Table 3.
iRGD conjugates used in treatment studies.
| Drug-peptide conjugates | |||
|---|---|---|---|
| Reference | Peptide | Drug | Tumor model |
| [10,25] | iRGD | Nab-paclitaxel | 22Rv1 human prostate cancer and BT474 human breast cancer xenografts |
| [77] | iRGD | Paclitaxel in nanoparticles | H22 murine liver cancer |
| [78] | iRGD | Thymopentin fused to iRGD | MCF7 human breast cancer xenograft |
| [79] | iRGD | Doxorubicin in chitosan nanoparticles | H22 murine liver cancer |
| [80] | iRGD | Doxorubicin liposomes | B16 mouse melanoma |
| [81] | iRGD | Doxorubicin multilamellar liposomes | 4T1 mouse mammary cancer |
| [82] | iRGD | Paclitaxel nanoparticles | C6 rat glioma |
| [83] | iRGD | Oncolytic virus | A549 human non-small cell lung carcinoma xenograft |
| [84] | iRGD | Paclitaxel liposomes | B16 mouse melanoma |
| [85] | iRGD | Paclitaxel and surviving siRNA in nanoparticles | A549 human non-small cell lung carcinoma xenograft |
| [86] | iRGD | Doxorubicin-containing exosomes | MDA-MB-231 human breast cancer xenograft |
| [87] | iRGD | ATAP mitochondrial targeting peptide | Du145 and PC3 human prostate cancer xenografts |
| [27] | iRGD | Anti-EGFR | BGC-823 human gastric adenocarcinoma xenograft |
| [88] | iRGD | Nanomicelles containing salinomycin | HepG2 human liver cancer xenograft |
| [89] | iRGD | Microbubbles for ultrasound imaging | 4T1 mouse mammary cancer |
| [90] | iRGD | Liposomal doxorubicin | B16 mouse melanoma |
| [91] | iRGD | Paclitaxel nano-crystallite | 4T1 mouse mammary cancer |
| [92] | iRGD | Combrestatin A4 and doxorubicin in nanoparticles | HeLa human cervical cancer |
| [31] | iRGD | Sorafenib in porous silicon nanoparticles | PC3-MM2 human prostate cancer xenograft |